Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Bolt Biotherapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 35
- −5 vs. Q2 2023
- Shares held
- 24.5M
- −523.9K (−2.1%) vs. Q2 2023
- Total value
- $25.5M
- −$6.56M (−20.4%) vs. Q2 2023
- New holders
- 3
- 8 more added
- Sold out
- 8
- 8 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 94 | $0 | 0.00% | +94 | New |
| Qube Research & Technologies Ltd | 2 | $2 | 0.00% | +2 | New |
| Salem Investment Counselors Inc | 40 | $42 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 86 | $89 | 0.00% | +86 | New |
| Barclays PLC | 139 | $145 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 197 | $205 | 0.00% | +39+24.7% | Added |
| Bank of America Corp | 628 | $653 | 0.00% | 00.0% | Unchanged |
| Federated Hermes, Inc. | 1,161 | $1.21K | 0.00% | −2,113−64.5% | Reduced |
| Northern Trust Corp | 31,182 | $32.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 44,983 | $46.8K | 0.00% | −69,006−60.5% | Reduced |
| State Street Corp | 48,737 | $50.7K | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 76,287 | $79.3K | 0.00% | −52,359−40.7% | Reduced |
| FMR LLC | 79,196 | $82.4K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 80,037 | $83.2K | 0.00% | +16,024+25.0% | Added |
| Marquette Asset Management, LLC | 97,835 | $101.7K | 0.02% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 111,200 | $115.6K | 0.00% | +10,000+9.9% | Added |
| Privium Fund Management (UK) Ltd | 116,516 | $121.2K | 0.09% | 00.0% | Unchanged |
| Morgan Stanley | 159,768 | $166.2K | 0.00% | +126,199+375.9% | Added |
| BlackRock Inc. | 258,023 | $268.3K | 0.00% | −29,868−10.4% | Reduced |
| Renaissance Technologies LLC | 314,189 | $327.0K | 0.00% | −169,750−35.1% | Reduced |
| Geode Capital Management, LLC | 360,739 | $375.2K | 0.00% | +8,520+2.4% | Added |
| Hawkeye Capital Management, LLC | 415,039 | $431.6K | 1.06% | 00.0% | Unchanged |
| Acuitas Investments, LLC | 460,379 | $478.8K | 0.28% | −60.0% | Reduced |
| Adage Capital Partners GP, L.L.C. | 500,000 | $520.0K | 0.00% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 757,097 | $787.4K | 0.06% | +37,551+5.2% | Added |
| Vanguard Group Inc | 924,265 | $961.2K | 0.00% | −4,011−0.4% | Reduced |
| Newtyn Management, LLC | 1,020,000 | $1.06M | 0.26% | +20,000+2.0% | Added |
| Samsara BioCapital, LLC | 1,049,153 | $1.09M | 0.33% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,166,952 | $1.21M | 0.98% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,541,000 | $1.60M | 0.04% | 00.0% | Unchanged |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $1.97M | 0.78% | 00.0% | Unchanged |
| Sofinnova Investments, Inc. | 2,754,437 | $2.86M | 0.20% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,853,634 | $2.97M | 0.00% | −132,513−4.4% | Reduced |
| Tang Capital Management LLC | 3,557,040 | $3.70M | 0.52% | +223,237+6.7% | Added |
| Vivo Capital, LLC | 3,871,291 | $4.03M | 0.50% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 0 | $0 | 0.00% | −284,170−100.0% | Sold out |
| Assenagon Asset Management S.A. | 0 | $0 | 0.00% | −158,289−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −24,400−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −13,309−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −12,578−100.0% | Sold out |
| Stifel Financial Corp | 0 | $0 | 0.00% | −12,264−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −652−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −400−100.0% | Sold out |